Biochemical Study of Isthmin-1 in Obese Males of Mosul City-Iraq

Abstract

Obesity represents a significant global health issue in the 21st century, as it is linked to a higher risk of numerous diseases. It significantly affects several body functions, including immune response, as well as the endocrine and paracrine functions of adipose tissue. Isthmin-1 is a newly identified adipokine with insulin-like properties, secreted by adipose tissue. It stimulates a series of signaling pathways like those triggered by insulin, enhancing glucose uptake, inhibiting lipid synthesis in the liver and promoting protein synthesis. In this study, 5 ml of blood samples were collected from 65 obese men aged between 18 and 60 years from hospitals in Mosul. Participants were categorized based on their body mass index (BMI). The findings revealed a significant elevation (P≤0.05) in isthmin-1 levels among obese individuals compared to the control group, with a positive correlation identified between isthmin-1 levels and BMI. Additionally, elevated levels of triglycerides and cholesterol were recorded in the obese group. The approximate molecular weight of isthmin-1 was also determined using biochemical techniques, it was found to be around 64 kilo daltons, with a specific activity of 7.48, a purification fold of 23.3, and a recovery rate of 77%.

Country : Iraq

1 Abeer A. Hazaa2 Safaa A. Al-Ameen

  1. College of Science, Department of Chemistry, University of Mosul, Mosul, Iraq
  2. College of Science, Department of Chemistry, University of Mosul, Mosul, Iraq

IRJIET, Volume 9, Issue 6, June 2025 pp. 1-5

doi.org/10.47001/IRJIET/2025.906001

References

  1. World Health Organization, “Obesity and overweight,” 9 June 2021. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  2. K. A. Erion and B. E. Corkey, “Hyperinsulinemia: a cause of obesity?” Curr. Obes. Rep., vol. 6, pp. 178–186, 2017.
  3. J. Cawley and C. Meyerhoefer, “The medical care costs of obesity: an instrumental variables approach,” J. Health Econ., vol. 31, no. 1, pp. 219–230, 2012.
  4. L. Liu et al., “Adipokines, adiposity, and atherosclerosis,” Cell. Mol. Life Sci., vol. 79, no. 5, p. 272, 2022.
  5. T. Farkhondeh et al., “An overview of the role of adipokines in cardiometabolic diseases,” Molecules, vol. 25, no. 21, p. 5218, 2020.
  6. C. Li, S. Zhong, S. Ni, Z. Liu, S. Zhang, and G. Ji, “Zebrafish Ism1 is a novel antiviral factor that positively regulates antiviral immune responses,” Dev. Comp. Immunol., vol. 125, p. 104210, 2021, doi: 10.1016/j.dci.2021.104210.
  7. Z. Jiang et al., “Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis,” Cell Metab., vol. 33, pp. 1836–1852.e11, 2021, doi: 10.1016/j.cmet.2021.07.010.
  8. J. Heeren and L. Scheja, “Isthmin 1 – a novel insulin-like adipokine,” Nat. Rev. Endocrinol., vol. 17, pp. 709–710, 2021.
  9. M. Lopez-Yus et al., “Isthmin-1 (ISM1), a novel adipokine that reflects abdominal adipose tissue distribution in individuals with obesity,” Cardiovasc. Diabetol., vol. 22, no. 1, p. 335, 2023, doi: 10.1186/s12933-023-02075-0.
  10. F. J. Ruiz-Ojeda et al., “Serum levels of the novel adipokine isthmin-1 are associated with obesity in pubertal boys,” World J. Pediatr., vol. 19, no. 3, pp. 256–266, 2023, doi: 10.1007/s12519-022-00665-8.
  11. F. J. Robyt and J. B. White, Biochemical Techniques: Theory and Practice, U.S.A.: Cole Publishing Co., 1987, pp. 141, 235–236, 246, 263, 296.
  12. V. W. Rodwell, D. A. Bender, K. M. Botham, P. J. Kennelly, and P. A. Weil, Harper's Illustrated Biochemistry, 30th ed., McGraw-Hill Education, 2018.
  13. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” J. Biol. Chem., vol. 193, no. 1, pp. 265–275, 1951.
  14. D. J. Holme and H. Peck, Analytical Biochemistry, New York: John Wiley & Sons, 1988, p. 86.
  15. G. R. Schacterle and S. Pollack, “A simplified method for the quantitative assay of small amounts of protein in biological materials,” Anal. Biochem., vol. 51, pp. 654–655, 1973.
  16. P. A. Felig and K. R. Feingold, “Obesity and dyslipidemia,” in Endotext, K. R. Feingold, Ed., National Center for Biotechnology Information (NCBI), 2023. [Online]. Available: https://www.endotext.org.
  17. H. E. Bays et al., “Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association,” Obes. Pillars, vol. 10, p. 100108, 2024, doi: 10.1016/j.obpill.2024.100108.
  18. C. Ó'Fágáin, P. M. Cummins, and B. F. O'Connor, “Gel-filtration chromatography,” Methods Mol. Biol., vol. 1485, pp. 15–25, 2017, doi: 10.1007/978-1-4939-6412-3_2.
  19. L. Menghuan et al., “Advances in research of biological functions of Isthmin-1,” J. Cell Commun. Signal., 2023, doi: 10.1007/s12079-023-00732-3.
  20. T. Li et al., “Crystal structure of Isthmin-1 and reassessment of its functional role in pre-adipocyte signaling,” Nat. Commun., vol. 16, p. 3580, 2025, doi: 10.1038/s41467-025-58828-w.
  21. T. Y. Ahmad, F. K. H. Tawfeeq, and S. A. Al-Ameen, “Biochemical study of dipeptidylpeptidase-4 from normal human serum,” Rafidain J. Sci., vol. 27, no. 1, pp. 123–132, 2018.